NCT04732494 (AdvanTIG-203) is a Phase 2 clinical trial of Tislelizumab in Esophageal Squamous Cell Carcinoma, sponsored by BeiGene.

Who is sponsoring NCT04732494?

NCT04732494 is sponsored by BeiGene.

What drugs are being tested in NCT04732494?

Interventions in NCT04732494: Tislelizumab, Ociperlimab, Placebo.

What condition does NCT04732494 study?

NCT04732494 studies Esophageal Squamous Cell Carcinoma.

Is NCT04732494 still recruiting?

NCT04732494 is currently completed. Last updated 31 January 2025.

Are results published for NCT04732494?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-01-31 · How we verify

NCT04732494: AdvanTIG-203

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

Completed Phase 2 Results posted Last updated 31 January 2025

What this trial tests

Phase 2 trial testing Tislelizumab in Esophageal Squamous Cell Carcinoma in 125 participants. Completed in 26 December 2023.

Timeline

31 March 2021

Primary endpoint
1 February 2023

26 December 2023

Quick facts

Lead sponsor	BeiGene
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	125
Start date	31 March 2021
Primary completion	1 February 2023
Estimated completion	26 December 2023
Sites	86 locations across France, Taiwan, South Korea, Thailand, China, Spain

Drugs / interventions tested

Tislelizumab (TISLELIZUMAB) — full drug profile →
Ociperlimab — full drug profile →
Placebo

Conditions studied

Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

BeiGene — full company profile →

Who can join

18 and older, any sex, with Esophageal Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Objective Response Rate (ORR) Assessed by the Investigator Primary · Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Objective response rate is defined as the percentage of participants who had a best overall response of confirmed complete response (CR) or partial response (PR) assessed by the Investigator according to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Response evaluations were performed using computed tomography or magnetic resonance imaging (MRI) approximately every 6 weeks for the first 54 weeks and then every 12 weeks thereafter. CR: Disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) \< 10 mm, and no new lesions.

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	30.6	19.6 – 43.7
Arm B: Tislelizumab Plus Placebo	20.6	11.5 – 32.7

Overall Survival Secondary · From randomization to the end of the study, median (range) time on follow-up was 10.0 (0.5 - 29.9) months in Arm A and 7.8 (0.4 - 29.3) months in Arm B.

Overall survival (OS) is defined as the time from the date of randomization until the date of death due to any cause. Median overall survival was estimated using the Kaplan-Meier method. For participants who were still alive at the end of the trial, OS was censored at the last known alive date or the date of data cutoff, whichever was earlier.

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	10.2	7.9 – 19.5
Arm B: Tislelizumab Plus Placebo	9.3	6.4 – 14.8

Objective Response Rate Assessed by the Independent Review Committee Secondary · Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Objective response rate is defined as the percentage of participants who had a best overall response of confirmed complete response (CR) or partial response (PR) assessed by the Independent Review Committee (IRC) according to RECIST v1.1. Response evaluations were performed using computed tomography or MRI approximately every 6 weeks for the first 54 weeks and then every 12 weeks thereafter. CR: Disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) \< 10 mm, and no new lesions. PR: At least a 30% decrease in the size of target lesion

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	32.3	20.9 – 45.3
Arm B: Tislelizumab Plus Placebo	25.4	15.3 – 37.9

Progression-free Survival (PFS) Assessed by the Independent Review Committee Secondary · From randomization up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Progression-free survival is defined as the time from the date of randomization to the date of first documentation of progressive disease assessed by the Independent Review Committee per RECIST v1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	3.6	2.7 – 5.1
Arm B: Tislelizumab Plus Placebo	2.8	1.9 – 6.9

Progression-free Survival (PFS) Assessed by the Investigator Secondary · From randomization to the end of the study, median (range) time on follow-up was 10.0 (0.5 - 29.9) months in Arm A and 7.8 (0.4 - 29.3) months in Arm B.

Progression-free survival is defined as the time from the date of randomization to the date of first documentation of progressive disease assessed by the Investigator per RECIST v1.1, or death, whichever occurred first. Median PFS was estimated using the Kaplan-Meier method. Progressive Disease (PD): At least a 20% increase in the size of target lesions with an absolute increase of at least 5 mm, or unequivocal progression of existing non-target lesions, or the appearance of any new lesions.

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	3.4	1.8 – 5.1
Arm B: Tislelizumab Plus Placebo	3.4	1.9 – 4.1

Duration Of Response (DOR) Assessed by the Independent Review Committee Secondary · From randomization up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Duration of response is defined as the time from the first determination of an objective response (CR or PR) until the first documentation of progressive disease as assessed by the Independent Review Committee per RECIST v1.1, or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	14.6	7.2 – NA
Arm B: Tislelizumab Plus Placebo	NA	4.2 – NA

Duration Of Response (DOR) Assessed by the Investigator Secondary · From randomization to the end of the study, median (range) time on follow-up was 10.0 (0.5 - 29.9) months in Arm A and 7.8 (0.4 - 29.3) months in Arm B.

Duration of response is defined as the time from the first determination of an objective response (CR or PR) until the first documentation of progressive disease as assessed by the Investigator per RECIST v1.1, or death, whichever occurred first. Median DOR was estimated using the Kaplan-Meier method.

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	11.3	5.7 – NA
Arm B: Tislelizumab Plus Placebo	NA	4.1 – NA

Disease Control Rate Assessed by the IRC And the Investigator Secondary · Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Disease Control Rate is defined as the percentage of participants who had confirmed CR, PR, or stable disease (SD) assessed by the IRC and the investigator per RECIST v1.1. Response evaluations were performed using computed tomography or MRI approximately every 6 weeks for the first 54 weeks and then every 12 weeks thereafter. CR: Disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) \< 10 mm, and no new lesions. PR: At least a 30% decrease in the size of target lesions, with no progression of non-target lesions and no new lesions, or

Investigator assessment

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	61.3	48.1 – 73.4
Arm B: Tislelizumab Plus Placebo	58.7	45.6 – 71.0

Independent Review Committee

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	64.5	51.3 – 76.3
Arm B: Tislelizumab Plus Placebo	58.7	45.6 – 71.0

Clinical Benefit Rate Assessed by the IRC and the Investigator Secondary · Up to the primary analysis data cutoff date of 01 February 2023; median (range) time on follow-up was 7.4 (0.5 - 20.1) months in Arm A and 6.4 (0.4 - 20.2) months in Arm B.

Clinical benefit rate is defined as the percentage of participants who achieved a confirmed complete response, partial response, or durable stable disease assessed by the IRC and the Investigator per RECIST v1.1. Response evaluations were performed using computed tomography or MRI approximately every 6 weeks for the first 54 weeks and then every 12 weeks thereafter. CR: Disappearance of all target and non-target lesions; any pathological lymph nodes (whether target or non-target) \< 10 mm, and no new lesions. PR: At least a 30% decrease in the size of target lesions, with no progression of n

Investigator Assessment

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	33.9	22.3 – 47.0
Arm B: Tislelizumab Plus Placebo	30.2	19.2 – 43.0

Independent Review Committee

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	32.3	20.9 – 45.3
Arm B: Tislelizumab Plus Placebo	27.0	16.6 – 39.7

Change From Baseline in European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30) Global Health Status (GHS)/Quality of Life (QOL) and Physical Functioning Scores Secondary · Baseline, Cycle 5 Day 1 and Cycle 7 Day 1 (each cycle was 3 weeks)

The EORTC QLQ-30 contains 30 questions that incorporate 5 functional scales (physical functioning, role functioning, emotional functioning, cognitive functioning, and social functioning), 1 global health status scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The participant answers questions about their health during the past week. There are 28 questions answered on a 4-point scale where 1 = Not at all (best) and 4 = Very Much (worst) and 2 global health quality of life

Global Health Status/QOL: Cycle 5

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	1.7	-5.6 – 8.9
Arm B: Tislelizumab Plus Placebo	-0.1	-7.5 – 7.4

Global Health Status/QOL: Cycle 7

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	0.3	-5.6 – 6.1
Arm B: Tislelizumab Plus Placebo	-2.8	-8.8 – 3.2

Physical Functioning: Cycle 5

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-0.5	-4.3 – 3.3
Arm B: Tislelizumab Plus Placebo	1.2	-2.8 – 5.2

Physical Functioning: Cycle 7

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-4.4	-11.2 – 2.5
Arm B: Tislelizumab Plus Placebo	-3.9	-11.0 – 3.3

Change From Baseline in EORTC Quality of Life Oesophageal Cancer Questionnaires 18 (QLQ-OES18) Dysphagia, Eating, Reflux and Pain Scales Secondary · Baseline, Cycle 5 Day 1 and Cycle 7 Day 1 (each cycle was 3 weeks)

The EORTC-QLQ-OES18 is the specific esophageal symptoms module of the QLQ-C30. QLQ-OES18 is comprised of 18 questions grouped into 4 multi-item subscales: Dysphagia (3 items), Eating (4 items), Reflux (2 items), and Pain (3 items) and 6 single item subscales (saliva swallowing, choking, dry mouth, taste, coughing, and talking). Participants indicate the extent to which they have experienced symptoms on a scale from 1 (Not at all) to 4 (Very much). Scores are calculated and transformed to a scale from 0 to 100; higher scores indicate a higher level of symptomatology or problems.

Dysphagia: Cycle 5

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-5.9	-14.2 – 2.4
Arm B: Tislelizumab Plus Placebo	4.1	-4.7 – 12.8

Dysphagia: Cycle 7

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-3.5	-15.4 – 8.5
Arm B: Tislelizumab Plus Placebo	7.3	-5.2 – 19.8

Eating: Cycle 5

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-1.6	-6.6 – 3.3
Arm B: Tislelizumab Plus Placebo	-1.3	-6.6 – 4.1

Eating: Cycle 7

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-2.8	-9.1 – 3.6
Arm B: Tislelizumab Plus Placebo	6.6	-0.2 – 13.4

Reflux: Cycle 5

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	1.9	-4.6 – 8.3
Arm B: Tislelizumab Plus Placebo	-0.4	-7.1 – 6.4

Reflux: Cycle 7

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	2.7	-4.8 – 10.1
Arm B: Tislelizumab Plus Placebo	4.0	-3.8 – 11.8

Pain: Cycle 5

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	0.1	-5.5 – 5.6
Arm B: Tislelizumab Plus Placebo	-0.7	-6.5 – 5.1

Pain: Cycle 7

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	-2.1	-7.1 – 3.0
Arm B: Tislelizumab Plus Placebo	3.3	-2.0 – 8.5

Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) Secondary · From first dose of study drug until 30 days after last dose; median duration of treatment was 3.45 months in Tislelizumab + Ociperlimab arm and 2.79 months in the Tislelizumab + Placebo arm.

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study drugs, whether related to study drugs or not. An SAE is any untoward medical occurrence that, at any dose: * Resulted in death * Was life-threatening * Required hospitalization or prolongation of existing hospitalization * Resulted in disability/incapacity * Was a congenital anomaly/birth defect * Was considered a significant medical AE by the Investigator based on medical judgement. AEs were considered "rela

Any TEAE

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	58
Arm B: Tislelizumab Plus Placebo	60

TEAE ≥ Grade 3

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	28
Arm B: Tislelizumab Plus Placebo	28

Serious AEs

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	27
Arm B: Tislelizumab Plus Placebo	28

Related SAEs

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	13
Arm B: Tislelizumab Plus Placebo	13

TEAEs Leading to Treatment Discontinuation

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	9
Arm B: Tislelizumab Plus Placebo	10

TEAEs Leading to Death (Excluding Due to Disease Under Study)

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	4
Arm B: Tislelizumab Plus Placebo	4

Any Immune-Mediated AE

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	31
Arm B: Tislelizumab Plus Placebo	21

Immune-Mediated AE ≥ Grade 3

Group	Value	95% CI
Arm A: Tislelizumab Plus Ociperlimab	8
Arm B: Tislelizumab Plus Placebo	3

Adverse events — posted to ClinicalTrials.gov

Time frame: All-cause mortality is reported from randomization through the end of study; up to 30 months. AEs are reported from first dose of study drug until 30 days after last dose; median duration of treatment was 3.45 months in Tislelizumab + Ociperlimab arm and 2.79 months in the Tislelizumab + Placebo arm.. Reporting threshold: 3%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Arm A: Tislelizumab Plus Ociperlimab

Serious: 27/62 (44%)

Deaths: 39/62

Arm B: Tislelizumab Plus Placebo

Serious: 28/63 (44%)

Deaths: 36/63

Serious adverse events (56 terms)

Reaction	System	Arm A: Tislelizumab Plus O…	Arm B: Tislelizumab Plus P…
Pneumonia	Infections and infestations	—	—
Pneumonitis	Respiratory, thoracic and mediastinal disorders	—	—
Oesophageal obstruction	Gastrointestinal disorders	—	—
Death	General disorders	—	—
Malaise	General disorders	—	—
Pyrexia	General disorders	—	—
Hyperglycaemia	Metabolism and nutrition disorders	—	—
Malnutrition	Metabolism and nutrition disorders	—	—
Tumour haemorrhage	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Anaemia	Blood and lymphatic system disorders	—	—
Angina unstable	Cardiac disorders	—	—
Arteriosclerosis coronary artery	Cardiac disorders	—	—
Immune-mediated myocarditis	Cardiac disorders	—	—
Myocarditis	Cardiac disorders	—	—
Pericardial effusion	Cardiac disorders	—	—
Tachycardia	Cardiac disorders	—	—
Adrenal insufficiency	Endocrine disorders	—	—
Hypophysitis	Endocrine disorders	—	—
Secondary adrenocortical insufficiency	Endocrine disorders	—	—
Dysphagia	Gastrointestinal disorders	—	—
Impaired gastric emptying	Gastrointestinal disorders	—	—
Inguinal hernia	Gastrointestinal disorders	—	—
Oesophageal fistula	Gastrointestinal disorders	—	—
Oesophageal stenosis	Gastrointestinal disorders	—	—
Oesophageal ulcer	Gastrointestinal disorders	—	—

Other adverse events (86 terms — click to expand)

Reaction	System	Arm A: Tislelizumab Plus O…	Arm B: Tislelizumab Plus P…
Anaemia	Blood and lymphatic system disorders	—	—
Hypothyroidism	Endocrine disorders	—	—
Constipation	Gastrointestinal disorders	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—
Weight decreased	Investigations	—	—
Hypoalbuminaemia	Metabolism and nutrition disorders	—	—
Diarrhoea	Gastrointestinal disorders	—	—
Alanine aminotransferase increased	Investigations	—	—
Hyponatraemia	Metabolism and nutrition disorders	—	—
Fatigue	General disorders	—	—
Aspartate aminotransferase increased	Investigations	—	—
Hypokalaemia	Metabolism and nutrition disorders	—	—
Rash	Skin and subcutaneous tissue disorders	—	—
Asthenia	General disorders	—	—
COVID-19	Infections and infestations	—	—
Upper respiratory tract infection	Infections and infestations	—	—
Lymphocyte count decreased	Investigations	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—
Thrombocytopenia	Blood and lymphatic system disorders	—	—
Nausea	Gastrointestinal disorders	—	—
Vomiting	Gastrointestinal disorders	—	—
Pyrexia	General disorders	—	—
Blood creatine phosphokinase increased	Investigations	—	—
Insomnia	Psychiatric disorders	—	—
Dyspnoea	Respiratory, thoracic and mediastinal disorders	—	—
Hypertension	Vascular disorders	—	—
Dysphagia	Gastrointestinal disorders	—	—
Gastrooesophageal reflux disease	Gastrointestinal disorders	—	—
Pneumonia	Infections and infestations	—	—
Neutrophil count decreased	Investigations	—	—
White blood cell count decreased	Investigations	—	—
Hypercalcaemia	Metabolism and nutrition disorders	—	—
Hypochloraemia	Metabolism and nutrition disorders	—	—
Cancer pain	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	—	—
Dizziness	Nervous system disorders	—	—
Headache	Nervous system disorders	—	—
Productive cough	Respiratory, thoracic and mediastinal disorders	—	—
Hyperthyroidism	Endocrine disorders	—	—

Most-reported serious reactions: Pneumonia, Pneumonitis, Oesophageal obstruction, Death, Malaise, Pyrexia, Hyperglycaemia, Malnutrition.

Data from ClinicalTrials.gov NCT04732494 adverse events section.

Sponsor's own description

A study of tislelizumab (BGB-A317) plus ociperlimab versus tislelizumab plus placebo as second-line treatment in participants with programmed cell death protein-ligand 1 (PD-L1) tumor area positivity (TAP) ≥ 10% unresectable, locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Immunosenescence: molecular mechanisms and diseases.
Liu Z, Liang Q, Ren Y, Guo C, et al · · 2023 · cited 554× · PMID 37179335 · DOI 10.1038/s41392-023-01451-2
Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations.
Butterfield LH, Najjar YG. · · 2024 · cited 210× · PMID 38057451 · DOI 10.1038/s41577-023-00973-8
TIGIT, the Next Step Towards Successful Combination Immune Checkpoint Therapy in Cancer.
Ge Z, Peppelenbosch MP, Sprengers D, Kwekkeboom J. · · 2021 · cited 166× · PMID 34367161 · DOI 10.3389/fimmu.2021.699895
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
Co-inhibition of TIGIT and PD-1/PD-L1 in Cancer Immunotherapy: Mechanisms and Clinical Trials.
Chu X, Tian W, Wang Z, Zhang J, et al · · 2023 · cited 147× · PMID 37291608 · DOI 10.1186/s12943-023-01800-3
Natural killer cells: a promising immunotherapy for cancer.
Chu J, Gao F, Yan M, Zhao S, et al · · 2022 · cited 140× · PMID 35606854 · DOI 10.1186/s12967-022-03437-0
Anti-TIGIT therapies for solid tumors: a systematic review.
Rousseau A, Parisi C, Barlesi F. · · 2023 · cited 111× · PMID 36933320 · DOI 10.1016/j.esmoop.2023.101184
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K, Uhl B, Krstic J, Szmyra M, et al · · 2021 · cited 87× · PMID 34948104 · DOI 10.3390/ijms222413311

Verify or expand the search:

Other trials of Tislelizumab

Trials testing the same drug.

NCT07469306 — Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07475026 — A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence · Phase 3 · not yet recruiting
NCT07528274 — Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure · Phase 2 · recruiting
NCT07290985 — AACR Adaptive Biomarker-Driven Organ Preservation Trial in Gastroesophageal Adenocarcinomas · Phase 2 · not yet recruiting
NCT07518706 — Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin · Phase 2 · not yet recruiting

Other recruiting trials for Esophageal Squamous Cell Carcinoma

Currently open trials in the same condition.

NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
NCT07385001 — A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as N · Phase 1, PHASE2 · recruiting
NCT07217171 — A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial · Phase 1 · recruiting
NCT07109726 — A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations · Phase 1, PHASE2 · recruiting
NCT07090499 — A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors · Phase 1 · recruiting

Other BeiGene trials

Trials by the same sponsor.

NCT07169331 — A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglob · Phase 4 · recruiting
NCT07100938 — A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheum · Phase 2 · active not recruiting
NCT07005713 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB- · Phase 1 · active not recruiting
NCT06906809 — Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants · Phase 1 · completed
NCT06803680 — A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04732494 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by BeiGene
Last refreshed: 31 January 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04732494.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing